Liren Qian

Associate Professor


Liren Qian has been in the field of medicine for more than 10 years, who devoted himself to hematology. He has published more than 20 papers and participated in one international book in the past 5 years. Citations of those papers have reached more than 300 times. He is professional in the diagnosis and treatment of leukemia, lymphoma and multiple myeloma, malignant blood system diseases and various kinds of anemia. He is also professional in the treatment of complex complications after hematopoietic stem cell transplantation. He led a project in China of “Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate(R-IDARAM) with radiotherapy for primary central nervous system lymphoma”. He proposed a comprehensive treatment combining internal radiotherapy by stereotactic brachytherapy, modified R-IDARAM and followed reduced external radiotherapy may be a new treatment concept for primary central nervous system lymphoma with higher efficiency and lower toxicity. He also reported the medical effect of hydrogen gas on hematopoietic system and GVHD.


Area of Interest

1) leukemia
2) lymphoma
3) multiple myeloma
4) hematopoietic stem cell transplantation
5) graft-versus-host disease
6) anemia

top publication

(1)Liren Qian*, Jianliang Shen, Jian Cen, Wenjie Yin, Yuanyuan Ma. Myelodysplastic syndrome with neutrophilic panniculitis: A report of two cases and a literature review. Oncol Lett. 2015 ;9(4):1954-1956.

(2)Liren Qian*, Wanxi Fu, Jianliang Shen, Agents for refractory/relapsed acute lymphocytic leukemia in adults. Eur Rev Med Pharmacol Sci. 2014;18(17):2465-74.

(3)Defeng Zhao, Liren Qian*, Jianliang Shen, Xiaopeng Liu, Congyong Li, Jian Cen, Yaming Wang, Ke Mei, Yuanyuan Ma, Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma, Journal of Cellular and Molecular Medicine, early online, Doi:10.1111/jcmm.12252, 2014

(4)Liren Qian*, Jianliang Shen, Defeng Zhao,Shuyi Pan, Successful Treatment of Hemorrhagic Cystitis After HLA-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation by Hyperbaric Oxygen, Transplantation, 97(7):e41-2,2014

(5) Defeng Zhao, Liren Qian*, Jianliang Shen, Acute myelocytic leukemia a patient with hemophagocytic lymphohistiocytosis. Oncology Letters In press, 2014

(6)Liren Qian, Ke Mei, Jianliang Shen*, Jianming Cai, Administration of Hydrogen-Rich Saline Protects Mice From Lethal Acute Graft-Versus-Host Disease (aGVHD), Transplantation,95(5),658-662,2013

(7)Liren Qian*, Zhengcheng Wu, Jianliang Shen, Advances in the treatment of acute graft-versus-host disease, Journal of Cellular and Molecular Medicine,17(8),966-975,2013

(8)Liren Qian*, Jianliang Shen, Yunhai Chuai, Jianming Cai, Hydrogen as a New Class of Radioprotective Agent, International Journal of Biological Sciences,9(9),887-894,2013

(9)Liren Qian*, Jianliang Shen, Hydrogen therapy may be an effective and specific novel treatment for Acute Graft-versus-host disease (GVHD), Journal of Cellular and Molecular Medicine,17(8),1059-1063,2013

(10)Liren Qian, Zhi Zhang, Jianliang Shen*, Yi Liu, Primary Bone Marrow B-Cell Non Hodgkin’s Lymphoma successfully treated with R-CHOP, West Indian Medical Journal,62(1),89-91,2013

(11)Liren Qian*, Jianliang Shen, Jianming Cai, Hydrogen therapy may be an effective and specific novel treatment for aplastic anemia, Medical Science Monitor,18(6),HY19-22,2012

(12)Liren Qian, et al. Radioprotective effect of hydrogen in cultured cells and mice,Free Radical Research, 2010;44(3):275-282.(Cover page article)

(13)Liren Qian, et al. The Potential Cardioprotective Effects Of Hydrogen In Irradiated Mice .Journal of Radiation Research, 2010 ;51 (6):741-747.

(14)Liren Qian, et al. The Hypothesis of an Effective, Safe and Novel Radioprotective Agent:Hydrogen-rich Solution;West Indian Medical Journal 2010;59(2):122-124.

(15)Liren Qian, et al.Hydrogen-rich PBS protects cultured human cells from ionizing radiation-induced cellular damage; NT& RP. 2010;25(1):23-29.